Premium
Early outcome of magnesium bioresorbable scaffold implantation in acute coronary syndrome—the initial report from the Magmaris‐ACS registry
Author(s) -
Wlodarczak Adrian,
Lanocha Magdalena,
Jastrzebski Artur,
Pecherzewski Maciej,
Szudrowicz Marek,
Jastrzebski Waldemar,
Nawrot Joanna,
Lesiak Maciej
Publication year - 2019
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.28036
Subject(s) - medicine , acute coronary syndrome , myocardial infarction , unstable angina , cardiology , conventional pci , population , revascularization , chest pain , stent , surgery , environmental health
Abstract Objectives The Magmaris‐ACS Registry is the first assessment of the Magmaris implantation in the acute coronary syndrome (ACS) population. Background Bioresorbable vascular scaffolds (BRS), the newest coronary stent technology, was developed to overcome the limitations of the metallic drug‐eluting stents (DES). Current promising data of the Magmaris in patients with stable angina have encouraged to validate the second generation BRS in ACS indications. Methods The study population consisted of the consecutive patients who underwent PCI with the Magmaris BRS in the settings of ACS. Patients with ST‐segment elevation myocardial infarction were excluded from enrolment. Baseline demographic and angiographic characteristics, as well as 30‐day and 6‐month clinical, follow up were prospectively analyzed. Results Fifty patients were enrolled at mean age 62.9 ± 8.4 years (unstable angina—52% and non‐ST‐segment myocardial infarction [NSTEMI]—48%). Treated fifty‐one de novo lesions were located in LAD (37%), LCx (14%), and RCA (49%), respectively. Angiographic success in the target lesion was 100%. One case of recurrent ischemia was observed a day after the index procedure, due to the significant distal edge dissection a regular metallic DES overlapping Magmaris was implanted. No other in‐hospital events occurred (procedural success 98%). Six‐Month follow up showed none device‐oriented endpoints such as cardiac mortality, target vessel myocardial infarction or target vessel revascularization. None early scaffold thrombosis was reported. Conclusion The use of the Magmaris BRS in non‐ST elevation ACS patient is associated with a procedural safety and promising early angiographic and clinical outcomes. Long‐term follow‐up and further evaluation in large prospective randomized controlled trials are needed.